Spravato (esketamine) is an FDA-approved treatment for adults experiencing treatment-resistant depression. As one of the most significant advancements in depression care in recent decades, it offers a new path forward for individuals who have not found relief with traditional antidepressant medications or therapy alone.
At Cura Behavioral Health, Spravato is provided within a structured, medically supervised outpatient setting. Our experienced clinical team delivers care in a way that prioritizes safety, consistency, and long-term outcomes. Treatment is not approached as a standalone service, but rather as part of a comprehensive and individualized mental health plan.
Spravato is administered as a nasal spray in-office under direct clinical supervision. Each session includes careful monitoring before, during, and after treatment to ensure patient safety and therapeutic response. Our team coordinates care across all phases of treatment, supporting patients throughout their journey.
Spravato utilizes esketamine, a compound derived from ketamine, and works differently than traditional antidepressants. Rather than targeting serotonin pathways, Spravato acts on the brain’s glutamate system, which plays a key role in neural communication, mood regulation, and cognitive flexibility.
By enhancing these pathways, Spravato may help improve mood, increase mental clarity, and support emotional regulation. Some patients begin to notice improvement within weeks, though individual response varies and ongoing clinical oversight remains essential.
Spravato is specifically indicated for individuals with treatment-resistant depression. This typically includes patients who have:
A comprehensive psychiatric evaluation is completed to determine if Spravato is an appropriate treatment option.
Each Spravato session is conducted in a certified treatment setting and follows a structured protocol. Patients self-administer the medication under the supervision of trained clinical staff and remain in the clinic for observation following administration.
During this time, patients are supported in a calm and comfortable environment. Because temporary side effects such as sedation or dissociation may occur, patients are required to arrange transportation home and avoid driving for the remainder of the day.
Treatment typically begins with more frequent sessions and transitions to a maintenance schedule based on clinical response.
If you’ve struggled with depression that hasn’t improved with other treatments, Spravato could be the breakthrough you’ve been seeking. Our team will conduct a comprehensive evaluation to determine if you’re a good candidate for this therapy.
Don’t let a mental health condition hold you back any longer. Schedule a consultation with Cura Behavioral Health today. Our experienced team is ready to answer your questions and create a personalized treatment plan tailored to your unique needs.
Spravato is administered in accordance with established medical guidelines. Common side effects may include temporary dizziness, nausea, fatigue, or dissociation. These effects are monitored closely during each visit and typically resolve within a short period.
Ongoing evaluation throughout treatment allows our providers to assess response, adjust care as needed, and ensure safety at every stage.
Join our newsletter to stay up to date on features and releases.
By subscribing you agree to with our Privacy Policy and provide consent to receive updates from our company.
Dr. Kevin Simonson, an esteemed Medical Director at Cura Behavioral Health, brings over 15 years of experience in psychiatry. A graduate from a top medical school, he specializes in the treatment of mood disorders and anxiety, employing a patient-centered approach. His dedication to evidence-based care and his commitment to advancing mental health practices have made him a respected figure in the field. Dr. Simonson’s leadership ensures the highest standard of care for the community at Cura Behavioral Health.
